

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

SKNO-1

RRID:CVCL_2196

Type: Cell Line

Proper Citation

RRID:CVCL_2196

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2196

Proper Citation: RRID:CVCL_2196

Description: Cell line SKNO-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia with maturation

Defining Citation: [PMID:7772516](#), [PMID:9738977](#), [PMID:10637496](#), [PMID:11753612](#), [PMID:15843827](#), [PMID:18385756](#), [PMID:25984343](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:36982453](#)

Comments: Characteristics: CSF2 dependent., Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SKNO-1

Synonyms: Skno-1, SKNO1

Cross References: ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473440, BioSample:SAMN10989585, cancercellines:CVCL_2196, Cell_Model_Passport:SIDM01864, Cosmic:787478, Cosmic:975301, Cosmic:1149337, Cosmic:1281353, Cosmic:1524841, Cosmic:2306239, Cosmic:2690678, DepMap:ACH-001656, DSMZ:ACC-690, DSMZCellDive:ACC-690, GEO:GSM236805, GEO:GSM236841, IARC_TP53:16154, JCRB:JCRB1170, Wikidata:Q54954758

ID: CVCL_2196

Record Creation Time: 20220427T221548+0000

Record Last Update: 20260815T235828+0000

Ratings and Alerts

No rating or validation information has been found for SKNO-1.

No alerts have been found for SKNO-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Liu Q, et al. (2026) DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia. British journal of haematology.

Clayfield L, et al. (2026) Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell reports, 45(2), 116875.

Su Y, et al. (2025) Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia. Cancer research, 85(21), 4122.

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. Advanced science (Weinheim, Baden-Wurtemberg, Germany), e11573.

Perzolli A, et al. (2025) PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia. Cancers, 17(2).

Tayari MM, et al. (2025) Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML. bioRxiv : the preprint server for biology.

Kellaway SG, et al. (2024) Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nature communications, 15(1), 1359.

Ng M, et al. (2023) Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15. *iScience*, 26(10), 107844.

Popescu B, et al. (2023) Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. *Cell reports. Medicine*, 4(11), 101290.

Pal D, et al. (2022) hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. *Cell reports. Medicine*, 3(8), 100717.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 26(13), 3371.

Martinez-Soria N, et al. (2018) The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. *Cancer cell*, 34(4), 626.

Greenblatt SM, et al. (2018) CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. *Cancer cell*, 33(6), 1111.